The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar ...

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio.

VEGF-A therapy has revolutionized treatment and visual outcomes for patients with neovascular age-related macular degeneration (nAMD). Ranibizumab, the first anti–VEGF-A agent to be FDA approved, was ...

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...

PST-611 is a first in class non-viral vectorized therapy for the treatment of dry AMD/GA coding for human transferrin. PulseSight Therapeutics SAS presented new data on its lead program PST-611, a DNA ...

Although intravitreal injections are a safe and effective form of drug delivery, the need for frequent injections and the corresponding disruptions to patients’ lives can pose a significant treatment ...

Clinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilledema.

The Healthcare Private Equity team has advised Retina Consultants of America (RCA) and Webster Equity Partners in the sale of RCA to Cencora. The Healthcare Private Equity team has advised Retina ...

The US Food and Drug Administration (FDA) has granted the lead asset for FELIQS, FLQ-101, Fast Track designation for the prevention of retinopathy of prematurity (ROP). According to a press release 1 ...

Srinivas R. Sadda, MD, described the advantages and disadvantages of the various imaging technologies used to evaluate GA at the AAO 2024 conference. Keeping a sharp eye on geographic atrophy (GA) ...